Blog / Archives
Second Quarter 2012 Review: Diagnostic Company Financial Summaries
Regroup and Look for Q4 Drivers A lackluster earnings quarter that evokes the blahs. The hottest Company in the sector Cepheid (CPHD $36.12), took an earnings hit, driving the stock down 30% to the...
Biotech Stocks Stall in Today’s Rally: Idenix Falls 29% Update 1 Aug 17
QQQs Outperforming Biotech ETFs IBB and XBI-Take a Little Off Biotech Stocks are weak again today with both ETFs showing distribution and momentum moving toward the bottom of the channel. Nothing...
Rayno Life Science Portfolio Notes: CPHD PCYC TMO
Biotechnology Sector Hit with Profit Taking This week's Barrons: The West Coast Was the Right Coast Wedbush ranked #1 in % change 6 mo (+12.75%), one year (+18.84%) and three year (81.05%) stock...
Stealth Rally Picks Up on EuroTawk From Mario Draghi
Vague talk about Monetary Actions in Europe Sparks Broad Three Day Rally It started yesterday with Draghi saying that ECB actions are being proposed that would reduce bond yields in Italy and...
Biotech Stocks Fly Over Macro Flack: ALXN, ILMN, REGN, TMO
Rayno Life Science Focus Stocks Are Strong-TMO Added Biopharmaceutical stocks continue their run today beginning with higher sales expectations for Regeneron(REGN $128) with their eye drug for...
Clinical Diagnostics Stocks Sell-Off on Cepheid (CPHD $33.25) Guidance Cut
AACC Meeting Hangover Begins With Cepheid Earnings Cuts--Stock Off 24% on Volume of 7M shares Cepheid (CPHD) a leader in molecular diagnostics, forecasted earnings of 38-42 cents a share for the...
Rayno Life Science Portfolio: Huge Year for Diagnostics and Tools Stocks
2012: Four Big Winners Up 30-40% in DX and Tools Portfolio: ABAX, EXAS, GPRO, ILMN In a volatile year with dire macro news and low growth forecasts the NASDAQ was up 10 % YTD and the Rayno Life...
Emerging Biomarker Face-Off: BGMD vs VRML
Vermillion Stock Outperforms BG Medicine Since April 3 On 4/3/12 we posted the biomarker challenge featuring two emerging public companies that have approved diagnostic products. In a few weeks we...
Rayno Biopharmaceuticals Portfolio Winners July ’12 YTD: ALXN,IMGN,PCYC,REGN,SGEN Etc.
Biotechnology Sector Remains Strong Despite High Valuations The Rayno Biopharmaceuticals Portfolio is outperforming most of the biotech indices and ETF's with many winners over 50% YTD. The best...
Supreme Court Obamacare Ruling: Mixed Reaction For Healthcare Stocks- Update 1 Market Soars
Update 1 Mid-day Trading -June 29 Bulls Back in Charge on EU Bank Bailout The market has forgotten about Obamacare and reverted to the number one market issue-Euro debt resolution. Here is a...